ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

ASCO

ASCO

In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.

Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.

Patients with relapsed small cell lung cancer now have more options according to study results first presented at the 2016 ASCO Annual Meeting, held June 3–7, 2016, in Chicago.

A novel first-in-class antibody can significantly extend median survival when added to standard chemotherapy for patients with advanced gastric cancer.

As part of our coverage of the annual ASCO conference, we spoke with Dr. Veronika Bachanova on the role of NK cell therapy in hematologic malignancies.

Matching targeted therapies to genetic abnormalities harbored by tumor types for which those therapies are not approved by the FDA might expand treatment options for some patients with advanced cancers.

The investigational biosimilar MYL-1401O has comparable efficacy and safety to the FDA-approved trastuzumab in metastatic HER2-positive breast cancer.

Pages

Subscribe to ASCO on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.